Jyong Biotech Ltd. (MENS)
NASDAQ: MENS · Real-Time Price · USD
2.050
+0.140 (7.33%)
At close: Oct 28, 2026, 4:00 PM EDT
2.050
0.00 (0.00%)
After-hours: Oct 28, 2026, 4:10 PM EDT
Jyong Biotech Earnings Call Transcripts
Fiscal Year 2026
-
MCS-2 is highlighted for its unique action and safety in treating benign prostatic hyperplasia, with the company among the first to secure FDA phase III approval for a botanical drug, positioning it for early market entry.